In October, we added 95 citations in DIDB, including 36 in vitro (with 16 articles published in Oct 2026) and 59 in vivo articles (with 36 articles published in Oct 2026). Four NDAs and 2 BLAs approved by the FDA in 2026, including apitegromab (ISEMBYLD), daraxonrasib (RASONQUE), floretyrosine F18 (PIXCLARA), insulin efsitora alfa (ONSWIK), rusfertide (MIMRYLO), and tebipenem (UTEBZI), were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.